Switch theme
Sign up to access all valuation multiples
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It has two reportable segments Plinabulin pipeline and the TPD platform.
2014
40
LTM Revenue n/a
LTM EBITDA n/a
$44.8M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
BeyondSpring has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, BeyondSpring achieved revenue of n/a and an EBITDA of -$8.5M.
BeyondSpring expects next 12-month revenue of XXX and NTM EBITDA of XXX
See BeyondSpring valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $1.8M | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$21.5M | -$8.5M | XXX | XXX | XXX |
| EBITDA Margin | -1230% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$33.3M | -$21.0M | XXX | XXX | XXX |
| Net Margin | -1901% | -Infinity% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, BeyondSpring's stock price is $1.
BeyondSpring has current market cap of $47.2M, and EV of $44.8M.
See BeyondSpring trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $44.8M | $47.2M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, BeyondSpring has market cap of $47.2M and EV of $44.8M.
BeyondSpring's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate BeyondSpring's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for BeyondSpring and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $44.8M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | -5.3x | XXX | XXX | XXX |
| P/E | -4.2x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -2.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpBeyondSpring's NTM/LTM revenue growth is n/a
BeyondSpring's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $0.2M for the same period.
Over next 12 months, BeyondSpring's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate BeyondSpring's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for BeyondSpring and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -100% | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | -61% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
BeyondSpring acquired XXX companies to date.
Last acquisition by BeyondSpring was XXXXXXXX, XXXXX XXXXX XXXXXX . BeyondSpring acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was BeyondSpring founded? | BeyondSpring was founded in 2014. |
| Where is BeyondSpring headquartered? | BeyondSpring is headquartered in United States of America. |
| How many employees does BeyondSpring have? | As of today, BeyondSpring has 40 employees. |
| Who is the CEO of BeyondSpring? | BeyondSpring's CEO is Dr. Lan Huang, PhD. |
| Is BeyondSpring publicy listed? | Yes, BeyondSpring is a public company listed on NAS. |
| What is the stock symbol of BeyondSpring? | BeyondSpring trades under BYSI ticker. |
| When did BeyondSpring go public? | BeyondSpring went public in 2017. |
| Who are competitors of BeyondSpring? | Similar companies to BeyondSpring include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of BeyondSpring? | BeyondSpring's current market cap is $47.2M |
| Is BeyondSpring profitable? | Yes, BeyondSpring is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
